About Paraneoplastic antigen Ma2
Paraneoplastic antigen Ma2 (PNMA2) is a protein
from Homo sapiens identified by UniProt accession
Q9UL42, 364 residues long.
MolForge cross-references it against 0 known binders and
154 disease associations.
Target properties
| Protein name | Paraneoplastic antigen Ma2 |
|---|
| UniProt accession | Q9UL42 |
|---|
| Gene | PNMA2 |
|---|
| Organism | Homo sapiens |
|---|
| Length | 364 residues |
|---|
| Molecular weight | — |
|---|
| EC numbers | — |
|---|
| Target class | UNCLASSIFIED |
|---|
| Subcellular location | — |
|---|
| Keywords | — |
|---|
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
|---|
| Druggability score | — |
|---|
| Pocket score | — |
|---|
| Max clinical phase | — |
|---|
Disease associations (154)
Diseases linked to this target (Open Targets).
- neurodegenerative disease · score 0.43
- body height · score 0.33
- neuroimaging measurement · score 0.25
- brain measurement · score 0.23
- facial morphology measurement · score 0.22
- brain volume measurement · score 0.19
- age at first sexual intercourse measurement · score 0.15
- cortical thickness · score 0.14
- diastolic blood pressure · score 0.12
- PHF-tau measurement · score 0.12
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
|---|
| AF-Q9UL42-F1 | alphafold | PREDICTED | 80.96 | — |
Amino-acid sequence (364 residues)
MALALLEDWC RIMSVDEQKS LMVTGIPADF EEAEIQEVLQ ETLKSLGRYR LLGKIFRKQE NANAVLLELL EDTDVSAIPS EVQGKGGVWK VIFKTPNQDT EFLERLNLFL EKEGQTVSGM FRALGQEGVS PATVPCISPE LLAHLLGQAM AHAPQPLLPM RYRKLRVFSG SAVPAPEEES FEVWLEQATE IVKEWPVTEA EKKRWLAESL RGPALDLMHI VQADNPSISV EECLEAFKQV FGSLESRRTA QVRYLKTYQE EGEKVSAYVL RLETLLRRAV EKRAIPRRIA DQVRLEQVMA GATLNQMLWC RLRELKDQGP PPSFLELMKV IREEEEEEAS FENESIEEPE ERDGYGRWNH EGDD
Explore Paraneoplastic antigen Ma2 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets